In this episode of IDEA Collider, host Mike Rea sits down with Nello Mainolfi, founder and CEO of Kymera Therapeutics. Nello shares his journey from medicinal chemist to biotech founder and discusses the opportunities and lessons learned from building a company at the forefront targeted protein degradation.

Episode Timestamps;

00:00 Welcome to Idea Collider

00:18 Kymera 2026 Catalysts

02:33 De Risking with Degraders

02:54 Targeted Protein Degradation 101

06:20 KT-621 STAT6 Degrader

08:16 Rethinking Type 2 Disease Treatment

12:21 Nello’s Path to CEO

16:32 Building a Standalone Biotech

23:19 Partnering with Big Pharma

26:51 Culture and Office Energy

32:03 Capital Plan and Potential Launches

36:24 Belief and Execution Mindset

39:00 Life Outside the Lab

40:07 Where to Follow Kymera

40:35 Closing Thanks

Don't forget to Like, Share, Subscribe, Rate, and Review!

Keep up with Nello Mainolfi & Kymera

LinkedIn: https://www.linkedin.com/in/nello-mainolfi-2b55421a/ or https://www.linkedin.com/company/kymeratherapeutics/

Website: https://www.kymeratx.com/

Follow IDEA Pharma On;

Website: https://www.ideapharma.com/

LinkedIn: https://www.linkedin.com/company/idea-pharma/

Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

Building the Future of Targeted Protein Degradation Medicines with Nello Mainolfi